Anti-Ro52 seropositivity as a diagnostic pitfall in myositis-specific/associated antibody panels after intravenous immunoglobulin: Direct evidence from product and paired patient sera.

Barbosa RDA, Shinjo SK

Open source

DOI
10.1111/vox.70420
Published
2026 Nov 9
Container
Vox sanguinis
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1111/vox.70420,
  title = {Anti-Ro52 seropositivity as a diagnostic pitfall in myositis-specific/associated antibody panels after intravenous immunoglobulin: Direct evidence from product and paired patient sera.},
  author = {Barbosa RDA and Shinjo SK},
  year = {2026},
  journal = {Vox sanguinis},
  doi = {10.1111/vox.70420},
  url = {https://doi.org/10.1111/vox.70420}
}

RIS

TY  - JOUR
TI  - Anti-Ro52 seropositivity as a diagnostic pitfall in myositis-specific/associated antibody panels after intravenous immunoglobulin: Direct evidence from product and paired patient sera.
AU  - Barbosa RDA
AU  - Shinjo SK
PY  - 2026
JO  - Vox sanguinis
DO  - 10.1111/vox.70420
UR  - https://doi.org/10.1111/vox.70420
ER  - 

APA

RDA, B., & SK, S. (2026). Anti-Ro52 seropositivity as a diagnostic pitfall in myositis-specific/associated antibody panels after intravenous immunoglobulin: Direct evidence from product and paired patient sera.. Vox sanguinis. https://doi.org/10.1111/vox.70420

Source records